Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of pelacarsen in Japanese participants from Lp(a)HORIZON
jRCT2031260071Not yet recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Open-label, single-arm trial of pelacarsen in cardiac morbidity and lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Novartis. Primary endpoint: Number of participants with adverse events. Planned start May 2026; status: not yet recruiting.
02
Drugs
pelacarsen
03
Conditions
cardiac morbiditylipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on jRCT2031260071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260071.